This is the authors' abstract. We don't add key points for this paper.
Calne and Kamada demonstrated that the liver is an “immunoprivileged” organ. Indeed, in some rodent and porcine strains, the liver is accepted without or with minimal immunosuppression (1). Liver transplant patients usually need less immunosuppression than recipients of other organs. In contrast with other organs, acute rejection of the liver has less impact on long-term graft survival. Histologically-proven episodes of liver acute rejection can sometimes be self-limiting. Finally, chronic rejection of the liver is rare: 2% versus 20% after transplantation of other solid organs. Mechanisms behind the “liver effect” are not completely elucidated but include both deletional and nondeletional pathways (2). Soluble MHC molecules released by the liver allograft act as blocking factor. More recently, it was shown that liver-derived donor cells induce peripheral clonal exhaustion and deletion through activation-induced cell death (AICD). Among nondeletional pathways, various mechanisms have been hypothesized, including anergy, Th2 deviation, and more recently the generation of regulatory cells (2). One characteristic of the liver effect is that it is specific and transferable to organs that are simultaneously transplanted, providing that they derive from the same donor. In rodents, liver grafts protect donor-specific (but not third-party) renal, cardiac, and pancreatic allografts from rejection. A delayed liver transplantation can even reverse an ongoing acute cellular rejection. Clinically, livers also protect accompanying organs from rejection and this has been particularly well-documented for the kidney. The bowel is extremely immunogenic and many attempts at intestinal transplantation (ITx) were defeated by severe rejection. Certain patients suffering from short-bowel syndrome have concomitant liver failure and are candidates for combined liver-bowel replacement. It was thought that this particular group of patients would be immunologically advantaged. Rodent studies in Paris demonstrated that a donor-specific liver induces tolerance to an intestinal graft, or at least reduces the amount of immunosuppression required to achieve engraftment (3). Interestingly, one of the first successful cases of ITx under cyclosporine was a combined liver-intestinal transplant (4). For some time, it was argued that combined liver transplantation was (the only) efficient strategy to promote intestinal engraftment and should even be considered in ITx candidates with a normal liver function. This proposal was abandoned when high-dose tacrolimus-based immunosuppression was introduced and proved superior to cyclosporine in controlling rejection. In addition, controlled studies in large animals showed that additional liver transplantation did not provide a clear immune advantage in isolated ITx tacrolimus-treated recipients (5). Finally, single-center analysis and early reviews of the Intestinal Transplant Registry (www.intestinaltransplant.org) did not show better graft survival in liver-intestine versus ITx alone recipients. Today the question of whether the “liver effect” applies to the intestine remains controversial. Why? Among organ allografts, the bowel—due to its unique antigen presentation capacity—is one of the most immunogenic. And the more immunogenic an organ is, the more difficult it is to induce tolerance. Tolerogenic strategies proven efficient in a particular organ do not necessarily operate in all. For example, skin grafts are not necessarily tolerized by protocols that are efficient for less immunogenic organs. In addition, if a biological effect is limited in intensity, it requires larger series of patients to be “unmasked.” ITx is a rare transplant procedure and single-center series are usually not sufficiently powered to detect such an effect. Finally, other confounding factors complicate the issue. First, liver-intestine transplants are usually sicker than isolated ITx, and this causes a state of immunocompetency which protects from rejection, but nonspecifically. Alternatively, liver-intestine transplants have a higher morbidity and mortality posttransplant, which introduces a bias in favor of isolated ITx recipients. Although small in size, the series reported by the Paris team in this issue of Transplantation by Jugie et al. represents a homogenous single-center cohort. Authors found less severe rejection and better graft survival in liver-intestine versus intestine alone recipients. Such a protective effect of the liver had not been clearly reported before. Interestingly, the immunosuppression used was light for this type of transplant: no induction, and a classical triple therapy with steroids, azathioprine, and tacrolimus (15 ng/ml). It is increasingly recognized that tolerance is an active immune response and that overimmunosuppression is counterproductive. High-dose steroids block AICD and cause rejection of otherwise spontaneously accepted liver grafts (2). High-dose calcineurin-inhibitors inhibit development of tolerogenic regulatory cells (6). It is therefore possible that heavy immunosuppression—popular in the past to prevent intestinal rejection—contributed to mask the protective effect of the liver. In the study from the Paris team, recipient characteristics were similar, excluding that an intrinsically reduced immunocompetence in liver-intestine patients would play a role in the differences observed. In concordance with these data, a recent review of the Intestinal Transplant Registry looking at patients who survived at least 1 year (to eliminate perioperative bias) also demonstrated better long-term graft survival in patients who also received a liver graft (David Grant, Brussels, June 2005). This study also brings new insight into the mechanisms of the liver effect. Interestingly, NF-kB expression was reduced on day 0 in liver-intestine recipients, and this could apparently not be explained by differences in donor factors or in graft quality. That early differences in ischemia-reperfusion injury and control of inflammation influence the later immunogenicity of the graft stresses the effect that innate immunity may have on adaptive immunity—an interaction increasingly recognized in transplant immunology—and to which the bowel may be particularly sensitive due to its sophisticated mucosal innate system and its large endotoxin content. Another interesting finding is that epithelial apoptotic body counts, so far a hallmark of rejection, were higher in liver-intestine recipients, even in the absence of rejection. If confirmed in other studies, these data would suggest that rejection may have been overdiagnosed (and perhaps overtreated) in the past. Biologically, there is no reason that the liver effect would not apply to the intestine. The effect has been probably more difficult to unmask in the clinic because the number of ITx is small, because the bowel is highly immunogenic, and because nonspecific factors have made the interpretation of the data difficult. In addition, overimmunosuppression may have masked this effect in the past.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Pirenne et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: